Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. - Wikidata - wikimedia - TriplyDB

Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.

Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q54350699

about

DNA Damage and Pulmonary Hypertension In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system The dual regulatory role of miR-204 in cancer Sex differences in the pulmonary circulation: implications for pulmonary hypertension Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension.Minireview: Thioredoxin-interacting protein: regulation and function in the pancreatic β-cell.Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease.Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.Heme biosynthesis modulation via δ-aminolevulinic acid administration attenuates chronic hypoxia-induced pulmonary hypertension.Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.Mechanisms and therapeutic potential of microRNAs in hypertension.Low-dose radiation affects cardiac physiology: gene networks and molecular signaling in cardiomyocytes.Regulation of ca(2+) signaling in pulmonary hypertension.Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels Higher Estradiol and Lower Dehydroepiandrosterone-Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men.Signal transduction in the development of pulmonary arterial hypertension Gender, sex hormones and pulmonary hypertension.Thioredoxin-interacting protein regulates insulin transcription through microRNA-204 Nur77 suppresses pulmonary artery smooth muscle cell proliferation through inhibition of the STAT3/Pim-1/NFAT pathway Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.Role of microRNAs in Vascular Remodeling.Relationships between vascular oxygen sensing mechanisms and hypertensive disease processes.Reactive oxygen species as therapeutic targets in pulmonary hypertension.The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future.STAT3 signaling in pulmonary arterial hypertension.Progress in solving the sex hormone paradox in pulmonary hypertension.Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease.Novel investigational therapies for treating pulmonary arterial hypertension.Advances in treatment of pulmonary arterial hypertension: patent review.The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies.Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.Update on novel targets and potential treatment avenues in pulmonary hypertension.Update on innovative initiatives for the American Journal of Physiology-Heart and Circulatory Physiology.Emerging Therapeutics in Pulmonary Hypertension.Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension.BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series).Myeloid-Derived Suppressor Cells and Pulmonary Hypertension

P2860

Q27005594-C24FA741-D654-4C3F-AE58-8ED75A72F316 Q27026337-AB881223-4762-4BFC-A12F-E2DDC4498099 Q28078421-A0C2FDEE-ED34-45EF-B95F-05D5C6889597 Q33568826-F35A8DA0-A045-4FE5-ADD8-36062234C126 Q33820667-F2F1FCDC-E56B-422C-9C30-FD5DABE91AAD Q33909537-99AE767B-CCAA-42B2-9A56-17D2BE10776B Q33977405-A0833C38-4837-411A-BDDB-869C14BD3ACF Q34317717-597D736A-46A6-42BE-BEA9-8AC4C92680E2 Q34958933-3A952D79-0661-40AF-8870-F04124FBA65B Q35275372-19E17AA9-170A-43DC-B4DC-D9D81CAFA947 Q35919662-B60D8A6B-C668-46F1-AB88-21F4B6CEE1A9 Q36016478-9CDDFD49-8BE6-46D7-95CE-A50848706A29 Q36173562-9E3D449A-EBEF-48EA-A44F-9C13E5642121 Q36422429-84F6C363-4685-46D8-90BB-05154286F431 Q36628777-04FF3EAC-3A47-4D32-97AB-E87820304DDB Q36722236-2E13EDAC-DD3E-470B-996A-2E3ED26EB293 Q36916062-6FD20C74-2412-4F10-8578-4256E4AB388B Q37133785-52E0831D-057C-4BA4-9DFF-5A33879774AC Q37133789-1C4B0F06-8ACA-4CC9-AC9F-14830E9F26CB Q37330393-BC411B39-E57F-4273-87F5-DA65D6CE88ED Q37596153-13175769-3D8B-4EC6-9598-AC81EFC4BFF0 Q37671277-5067F8B4-4809-410F-80E5-D0342E557F1D Q37741544-1BC32098-3644-47B5-BCD6-A4B7CC1A32C8 Q38019769-1F55F0B3-B953-4654-8AAD-B997AA5A31C6 Q38074770-22762B70-C44E-4AE7-9A28-40BFA63DFF90 Q38077796-E35F6F91-E013-42DC-B9DC-D46F13F34466 Q38140894-62E4062E-9237-46C0-9307-BBF2326DB281 Q38210880-805A6233-BF51-4399-A638-E829050E6823 Q38266683-8C416312-9768-4146-AF1C-B04BCBD83E65 Q38612061-96BD28F7-C9F7-4CB9-9D53-0745E957F0D8 Q39206788-BC4AD9C6-FDFC-4F10-AB25-62429BFEC912 Q39353707-BAA2071F-51F1-4A9F-A937-2DAC7C128993 Q42746715-CC226690-F7A8-4FE6-8682-39D5FBF16ABA Q42784219-9C09024F-3DDE-4A03-B52F-D3299EB8381D Q44132620-93618C6C-54FF-44AC-AC25-BFCFDA17F39F Q47700134-0E711322-BA6C-4542-89F4-183811AB82D7 Q51069073-DAA48CA5-16ED-45C1-959B-9E59DBF21DDE Q55008475-7F626EE5-5569-4807-A87E-CE847D38126E Q58800964-5E0CEE68-5C6A-4779-B879-51F5C742B01B

P2860

Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q54350699

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Dehydroepiandrosterone inhibit ...... lmonary arterial hypertension.

@en

Dehydroepiandrosterone inhibit ...... lmonary arterial hypertension.

@nl

type

label

Dehydroepiandrosterone inhibit ...... lmonary arterial hypertension.

@en

Dehydroepiandrosterone inhibit ...... lmonary arterial hypertension.

@nl

prefLabel

Dehydroepiandrosterone inhibit ...... lmonary arterial hypertension.

@en

Dehydroepiandrosterone inhibit ...... lmonary arterial hypertension.

@nl

P1433

Q54350699-3AF5E1FA-C121-4474-AEE3-A7DC2B1AAA51

P1476

Q54350699-A6E773F4-880B-43ED-9742-919D8FF63508

P2093

Q54350699-775B1423-5B23-4AA3-B128-7C1D3B982755

Q54350699-78F0F3EA-FB82-420F-B763-F17D049A0418

Q54350699-A2B58F34-97CC-4B72-8EB8-F9235DE1E581

Q54350699-EFBED533-29FA-424A-86AC-4FD409D3B097

Q54350699-FE3E6FFF-49D7-4854-A086-86F5F95C5441

P2860

Q54350699-07309D69-D0F1-4260-91AE-67E1FDC6F4F0

Q54350699-07A6E96A-6037-4D5C-97C0-CFBF44CAC01F

Q54350699-1B35DE61-34EB-4BBF-B89B-61B91A0719B6

Q54350699-1CC40C1E-6F03-4519-8C6B-1D2CDC7CC1CD

Q54350699-2245AEF4-C60E-4578-8DA5-FA672F81255E

Q54350699-28ADD050-C9EE-47DE-81F1-F1CB847F2E91

Q54350699-29B5DAE1-E88C-4F39-8E1E-867FD2E40598

Q54350699-2C891963-C971-4FAC-B507-E29E98B0152B

Q54350699-2DF97DA5-7BF5-45BD-A326-0B6C2B927388

Q54350699-3EE9F914-7E29-4E10-98AE-76E22B5E1E15

P304

Q54350699-D657AADE-AD5C-40B5-A065-4B0AAC6496A2

P31

Q54350699-890081AE-8B47-4520-86AA-5047FB6A844B

P356

Q54350699-648724AC-749B-47E9-A4F5-49B715FAA14E

P433

Q54350699-BDD38A0C-0D76-4A07-9416-E2AA1079EBA9

P478

Q54350699-5D239E12-EDC5-4436-AE88-683021716140

P50

Q54350699-E117D233-E3AA-48E6-AE28-B5E38C8C79B1

P577

Q54350699-CF6FE826-FE6B-48F9-8A24-62B27806374C

P5875

Q54350699-04C6F1B3-09A0-4F3B-B425-72BCF1D86411

P698

Q54350699-C858F499-A32A-4BD8-BE8C-B95BD93A989F

P356

AJPHEART.00654.2011

P1433

American Journal of Physiology - Heart and Circulatory Physiology

P1476

Dehydroepiandrosterone inhibit ...... ulmonary arterial hypertension

@en

P2093

Audrey Courboulin

http://www.w3.org/2001/XMLSchema#string

Jolyane Meloche

http://www.w3.org/2001/XMLSchema#string

Maria Helena Jacob

http://www.w3.org/2001/XMLSchema#string

Roxane Paulin

http://www.w3.org/2001/XMLSchema#string

Sébastien Bonnet

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6

STATs and gene regulation

Primary pulmonary hypertension: a vascular biology and translational research "Work in progress".

Mitochondrial integrity: preservation through Akt/Pim-1 kinase signaling in the cardiomyocyte

Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.

Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation

Reversal of experimental pulmonary hypertension by PDGF inhibition.

P304

H1798-809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00654.2011

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

301

http://www.w3.org/2001/XMLSchema#string

P50

Malik Bisserier

P577

2011-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51617943

http://www.w3.org/2001/XMLSchema#string

P698

21890685

http://www.w3.org/2001/XMLSchema#string